F.D.A. Turmoil Keeps Spotlight on Its Commissioner

Start
The agency’s high-level turnover and conflicting policy decisions on drug oversight have fueled concerns about the leadership of Dr. Marty Makary.
Previous Story

How Much More Can the U.S. Travel Industry Take?

Next Story

U.S. Will Pay $450,000 to Wildfire Fighters With Cancer